Funding for this research was provided by:
Received: 4 February 2022
Accepted: 28 April 2022
First Online: 25 May 2022
: Akihisa Imagawa received honorarium for lectures from Astellas Pharma Inc.; clinical commissioned/joint research grant from Astra Zeneca, Soiken Inc., Taiho Pharmaceutical Co., Ltd., Daiichi Sankyo Co., Ltd., and Merck KGaA, Parexel International Inc.; research grant from Shionogi Co., Ltd., Sumitomo Dainippon Pharma Co., Ltd., Takeda Pharmaceutical Company, and Shionogi & Co., Ltd. The other authors declare no conflict of interest.
: This study was approved by the ethics committee of Osaka Medical and Pharmaceutical University on May 1, 2018, as No.2439 and done according to the principles of the “Declaration of Helsinki.”
: Informed consent was obtained in the form of an opt-out on the website.